AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2014
May 9, 2014
34113_dirs_2014-05-08_e8d5a065-d478-404f-ae71-318826a661e8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2014-05-06
Reporting Person: Remmel H. Lawrence (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-05-06 | Stock Option (right to buy) | $1.22 | A | 15000 | Acquired | 2024-05-06 | Common Stock (15000) | Direct |
Footnotes
F1: The option shall vest on a quarterly basis over the next twelve months.
More from ATOSSA THERAPEUTICS, INC.
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Declaration of Voting Results & Voting Rights Announcements
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 20
Capital/Financing Update
2026
Feb 20
Delisting Announcement
2026
Feb 17
Regulatory Filings
2026
Feb 11